Evaluating efficacy and safety of ocrelizumab biosimilar (Xacrel) compared to the originator (Ocrevus) in relapsing multiple sclerosis: a phase III, randomized, equivalency, clinical trial.
Sahraian MA, Abolfazli R, Shaygannejad V, Ashtari F, Majdinasab N, Navardi S, Baghbanian SM, Sedighi B, Naser Moghadasi A, Nahayati MA, Ghalyanchi Langroodi H, Mohammadianinejad SE, Beladi Moghadam N, Ayromlou H, Nikseresht A, Ghiasian M, Razazian N, Asadollahzadeh E, Sabzvari A, Kafi H, Albooyeh S.
Sahraian MA, et al. Among authors: naser moghadasi a.
Sci Rep. 2024 Oct 22;14(1):24921. doi: 10.1038/s41598-024-75745-y.
Sci Rep. 2024.
PMID: 39438591
Free PMC article.
Clinical Trial.